Loading
A phase 2 trial of Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab and Trastuzumab deruxtecan in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) is a phase 2 interventional study registered as NCT04379596 by AstraZeneca, with 452 participants enrolled, started 2020-06-03 and due to reach its primary completion in 2027-05-04. Interventions recorded: Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab and Trastuzumab deruxtecan.
Shares HER2-positive gastric cancer, Daiichi Sankyo, Trastuzumab deruxtecan, Trastuzumab and the tag pipeline.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares HER2-positive gastric cancer, Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Durvalumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares HER2-positive gastric cancer, Oxaliplatin, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine and the tag pipeline.
Shares Oxaliplatin, Trastuzumab, Capecitabine, Monoclonal antibodies and the tag pipeline.
Shares Oxaliplatin, Trastuzumab, Capecitabine, Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab deruxtecan, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag pipeline.